FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912672173> ?p ?o ?g. }

• W2912672173 abstract "Background Menorrhagia or heavy menstrual bleeding (HMB) is an excessive blood loss that impairs a woman's quality of life, either physical, emotional, social or material. It is benign and not associated with pregnancy or any other gynaecological or systemic disease. Medical treatments used to reduce excessive menstrual blood loss (MBL) include prostaglandin synthetase inhibitors, antifibrinolytics, oral contraceptive pills, and other hormones. The combined oral contraceptive pill (COCP) is claimed to have a variety of beneficial effects, inducing a regular shedding of a thinner endometrium and inhibiting ovulation, thus having the effect of both treating HMB and providing contraception. More recently, a contraceptive vaginal ring (CVR) has been trialled to investigate whether this treatment can provide similar benefits to COCP while lessening hormonal systemic exposure. This review is an update of a review which originally focused on COCP alone. The scope of the review has been widened to consider other types of delivery of combined hormonal contraceptives for reduction of MBL. Objectives To determine the efficacy of combined hormonal contraceptives (pills, vaginal ring or patch) compared with other medical therapies, placebo, or no therapy in the treatment of HMB. A secondary objective was to compare the COCP with the CVR. Search methods We searched the Gynecology and Fertility Group trials register, MEDLINE, Embase, CENTRAL, CINAHL and PsycINFO (search dates: Oct 1996, May 2002, June 2004, April 2006, June 2009, July 2017 and September 2018) for all randomised controlled trials (RCTs) of COCP and CVR for the treatment of HMB. We also searched trial registers and the reference lists of retrieved studies for additional trials. Selection criteria We included randomised controlled trials (RCTs) of the use of COCP or CVR compared with no treatment, placebo, or other medical therapies for women with HMB and regular menstrual cycles. Data collection and analysis All assessments of trial quality and data extraction were performed unblinded by at least two review authors. Our primary review outcomes were treatment success, menstrual bleeding (assessed objectively, semi‐objectively or subjectively), and participant satisfaction with treatment. Secondary outcomes were adverse events, quality of life, and haemoglobin level. Main results We identified eight RCTs involving 805 participants. Two trials comparing COCP with placebo were considered to be moderate quality and the remaining studies were low to very low quality, mainly because of serious risk of bias from lack of blinding and concerns over precision. COCP versus placebo COCP, with a step‐down oestrogen and step‐up progestogen regimen, improved response to treatment (return to menstrual 'normality') (OR 22.12, 95% CI 4.40 to 111.12; 2 trials; 363 participants; I2 = 50%; moderate‐quality evidence), and lowered MBL (OR 5.15, 95% CI 3.16 to 8.40; 2 trials; 339 participants; I2 = 0%; moderate‐quality evidence) when compared to placebo. The results suggested that, if the chance of 'successful' treatment was 3% in women taking placebo, then COCP increased this chance from 12% to 77% in women with unacceptable HMB. Minor adverse events, in particular breast pain, were more common with COCP. No study in this comparison reported semi‐objectively assessed MBL or participant satisfaction with treatment. COCP versus other medical treatments Non‐steroidal anti‐inflammatory drugs (NSAIDs) There was insufficient evidence to determine whether the COCP reduced MBL when compared to NSAIDs (mefenamic acid and naproxen). No study in this comparison reported semi‐objectively assessed MBL, subjectively assessed MBL, participant satisfaction with treatment or adverse events. Levonorgestrel‐releasing intrauterine system (LNG IUS) The LNG IUS was more effective than COCP in reducing MBL (OR 0.21, 95% CI 0.09 to 0.48; 2 trials; 151 participants; I2 = 0%; low‐quality evidence) but it was not clear whether satisfaction with treatment or adverse effects varied according to which treatment was used. No study in this comparison reported semi‐objectively assessed MBL or subjectively assessed MBL. Contraceptive vaginal ring (CVR) versus other medical treatments COCP COCP was compared with CVR in two trials. There were discrepancies between some of the findings and there was no evidence of a benefit for one treatment compared to the other for response to treatment, MBL or participant satisfaction with treatment. There was a greater likelihood of nausea with COCP. No study in this comparison reported objectively assessed MBL or subjectively assessed MBL. Progestogens CVR was compared to long course progestogens in one trial. It is possible that CVR increased the odds of satisfaction; but we are uncertain whether CVR improved MBL. The evidence was based on small numbers of participants and was very low quality, so definitive conclusions could not be reached. No study in this comparison reported objectively assessed MBL, subjectively assessed MBL, or adverse events. Authors' conclusions Moderate‐quality evidence suggests that the combined oral contraceptive pill over six months reduces HMB in women with unacceptable HMB from 12% to 77% (compared to 3% in women taking placebo). When compared with other medical options for HMB, COCP was less effective than the LNG IUS. Limited evidence suggested that COCP and CVR had similar effects. There was insufficient evidence to determine comparative efficacy of combined hormonal contraceptives with NSAIDs, or long course progestogens." @default.
• W2912672173 created "2019-02-21" @default.
• W2912672173 creator A5009731454 @default.
• W2912672173 creator A5049777809 @default.
• W2912672173 creator A5056561500 @default.
• W2912672173 creator A5057008392 @default.
• W2912672173 creator A5082542948 @default.
• W2912672173 date "2019-02-11" @default.
• W2912672173 modified "2023-10-01" @default.
• W2912672173 title "Combined hormonal contraceptives for heavy menstrual bleeding" @default.
• W2912672173 cites W1512767282 @default.
• W2912672173 cites W1662995627 @default.
• W2912672173 cites W1735131153 @default.
• W2912672173 cites W1955491160 @default.
• W2912672173 cites W1975560573 @default.
• W2912672173 cites W1976456116 @default.
• W2912672173 cites W1976471861 @default.
• W2912672173 cites W1984996934 @default.
• W2912672173 cites W1999128252 @default.
• W2912672173 cites W2012165536 @default.
• W2912672173 cites W2015985197 @default.
• W2912672173 cites W2021760239 @default.
• W2912672173 cites W2023952454 @default.
• W2912672173 cites W2032832595 @default.
• W2912672173 cites W2035353244 @default.
• W2912672173 cites W2042374015 @default.
• W2912672173 cites W2049676614 @default.
• W2912672173 cites W2058328318 @default.
• W2912672173 cites W2063032334 @default.
• W2912672173 cites W2067183284 @default.
• W2912672173 cites W2068241955 @default.
• W2912672173 cites W2070796663 @default.
• W2912672173 cites W2074364609 @default.
• W2912672173 cites W2081092254 @default.
• W2912672173 cites W2084628566 @default.
• W2912672173 cites W2090979444 @default.
• W2912672173 cites W2093695518 @default.
• W2912672173 cites W2097904958 @default.
• W2912672173 cites W2101146672 @default.
• W2912672173 cites W2102492167 @default.
• W2912672173 cites W2107885242 @default.
• W2912672173 cites W2118699303 @default.
• W2912672173 cites W2120835813 @default.
• W2912672173 cites W2125950103 @default.
• W2912672173 cites W2131168281 @default.
• W2912672173 cites W2135315003 @default.
• W2912672173 cites W2157256729 @default.
• W2912672173 cites W2167806966 @default.
• W2912672173 cites W2263521446 @default.
• W2912672173 cites W2339383574 @default.
• W2912672173 cites W2396609641 @default.
• W2912672173 cites W2522737069 @default.
• W2912672173 cites W2809861734 @default.
• W2912672173 cites W2904259009 @default.
• W2912672173 cites W3470488 @default.
• W2912672173 cites W4241168317 @default.
• W2912672173 cites W4281727314 @default.
• W2912672173 doi "https://doi.org/10.1002/14651858.cd000154.pub3" @default.
• W2912672173 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6369862" @default.
• W2912672173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30742315" @default.
• W2912672173 hasPublicationYear "2019" @default.
• W2912672173 type Work @default.
• W2912672173 sameAs 2912672173 @default.
• W2912672173 citedByCount "33" @default.
• W2912672173 countsByYear W29126721732012 @default.
• W2912672173 countsByYear W29126721732019 @default.
• W2912672173 countsByYear W29126721732020 @default.
• W2912672173 countsByYear W29126721732021 @default.
• W2912672173 countsByYear W29126721732022 @default.
• W2912672173 countsByYear W29126721732023 @default.
• W2912672173 crossrefType "journal-article" @default.
• W2912672173 hasAuthorship W2912672173A5009731454 @default.
• W2912672173 hasAuthorship W2912672173A5049777809 @default.
• W2912672173 hasAuthorship W2912672173A5056561500 @default.
• W2912672173 hasAuthorship W2912672173A5057008392 @default.
• W2912672173 hasAuthorship W2912672173A5082542948 @default.
• W2912672173 hasBestOaLocation W29126721732 @default.
• W2912672173 hasConcept C131872663 @default.
• W2912672173 hasConcept C142724271 @default.
• W2912672173 hasConcept C204787440 @default.
• W2912672173 hasConcept C27081682 @default.
• W2912672173 hasConcept C2776172332 @default.
• W2912672173 hasConcept C2779076696 @default.
• W2912672173 hasConcept C2779755712 @default.
• W2912672173 hasConcept C2908647359 @default.
• W2912672173 hasConcept C29456083 @default.
• W2912672173 hasConcept C2986817661 @default.
• W2912672173 hasConcept C71924100 @default.
• W2912672173 hasConcept C81603835 @default.
• W2912672173 hasConcept C98274493 @default.
• W2912672173 hasConcept C99454951 @default.
• W2912672173 hasConceptScore W2912672173C131872663 @default.
• W2912672173 hasConceptScore W2912672173C142724271 @default.
• W2912672173 hasConceptScore W2912672173C204787440 @default.
• W2912672173 hasConceptScore W2912672173C27081682 @default.
• W2912672173 hasConceptScore W2912672173C2776172332 @default.
• W2912672173 hasConceptScore W2912672173C2779076696 @default.
• W2912672173 hasConceptScore W2912672173C2779755712 @default.
• W2912672173 hasConceptScore W2912672173C2908647359 @default.
• W2912672173 hasConceptScore W2912672173C29456083 @default.

• next